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ABSTRACT
Objective Contrary to the long-standing prerequisite of
inducing selective (ie, biﬁdogenic) effects, recent ﬁndings
suggest that prebiotic interventions lead to ecosystem-
wide microbiota shifts. Yet, a comprehensive
characterisation of this process is still lacking. Here, we
apply 16S rDNA microbiota proﬁling and matching (gas
chromatography mass spectrometry) metabolomics to
assess the consequences of inulin fermentation both on
the composition of the colon bacterial ecosystem and
faecal metabolites proﬁles.
Design Faecal samples collected during a double-blind,
randomised, cross-over intervention study set up to
assess the effect of inulin consumption on stool
frequency in healthy adults with mild constipation were
analysed. Faecal microbiota composition and metabolite
proﬁles were linked to the study’s clinical outcome as
well as to quality-of-life measurements recorded.
Results While faecal metabolite proﬁles were not
signiﬁcantly altered by inulin consumption, our analyses
did detect a modest effect on global microbiota
composition and speciﬁc inulin-induced changes in
relative abundances of Anaerostipes, Bilophila and
Biﬁdobacterium were identiﬁed. The observed decrease
in Bilophila abundances following inulin consumption
was associated with both softer stools and a favourable
change in constipation-speciﬁc quality-of-life measures.
Conclusions Ecosystem-wide analysis of the effect of a
dietary intervention with prebiotic inulin-type fructans on
the colon microbiota revealed that this effect is
speciﬁcally associated with three genera, one of which
(Bilophila) representing a promising novel target for
mechanistic research.
Trial registration number NCT02548247.
INTRODUCTION
The prebiotic concept was introduced in 1995,
referring to a ‘non-digestible food ingredient that
beneﬁcially affects the host by selectively stimulat-
ing the growth and/or activity of one or a limited
number of bacteria in the colon, and thus improves
health’.1 Ever since, proposals to amend this deﬁn-
ition have been made on a regular basis. Recent
amendments proposed the extension of the
concept to body sites other than the large intestine
as well as the inclusion of beneﬁts on host well-
being as intervention targets, but also the removal
of the restriction of selectivity of a prebiotic effect
on colon ecosystem composition.2 3 The latter is
remarkable, since the prebiotic concept emerged
from observations of selective stimulation of
Biﬁdobacterium growth on inulin fermentation.4–6
However, the targeted nature of the methods most
often used in prebiotic research to quantify bacter-
ial abundances does not allow to exclude a pre-
biotic effect beyond the taxonomic clusters under
investigation.3 Using sequencing approaches that do
allow microbiota-wide assessment of relative abun-
dance shifts, two recent mice studies indicated a
broad-spectrum response of the gut microbial com-
munity following prebiotic stimulation,7 8 resulting
from both expected cross-feeding interactions and
changes in the gut environment.9 Next to the
Signiﬁcance of this study
What is already known on this subject?
▸ Dietary interventions with prebiotics constitute
one of the main strategies to modulate gut
microbiota composition and activity.
▸ The effect of consumption of inulin-type
fructans on the colon Biﬁdobacterium
population is well documented.
▸ With recent ﬁndings in mice studies pointing
towards a broad-spectrum effect, the speciﬁcity
of a prebiotic effect has become subject of
debate.
What are the new ﬁndings?
▸ Inulin-type fructans have a selective effect on
the human gut microbiota.
▸ The only genera consistently impacted by inulin
supplementation are Biﬁdobacterium,
Anaerostipes and Bilophila.
▸ Decreased Bilophila abundance on inulin
consumption is linked with improved
constipation-related quality-of-life metrics.
How might it impact on clinical practice in
the foreseeable future?
▸ This study is the ﬁrst to assess the effect of a
dietary inulin intervention on the gut
microbiota using next-generation sequencing
technology. The demonstrated selectivity of the
effect of inulin allows customised interventions
based on the nature of the dysbiosis targeted.
The link between Bilophila abundance and
well-being combined with the susceptibility of
the genus to inulin interventions opens new
perspectives for prebiotic research.
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growing consensus regarding a community-level microbiota
response to prebiotics, the necessity of selective bacterial stimu-
lation to enable a beneﬁcial effect on host health has also been
questioned.3 Many projected health beneﬁts of prebiotic inter-
ventions are attributed to enhanced saccharolytic fermentation
and the resulting increased production of short-chain fatty
acids10 – both common features among colon bacteria.11 Hence,
an emerging opinion in the ﬁeld is that the requirement of
selectivity of prebiotic stimulation is unnecessarily strict – an
opinion that has grown to become a topic of hot debate both in
academia and industry.2
To date, the impact of prebiotic interventions on the totality
of the human colon bacterial ecosystem has not been investi-
gated using meta-omics approaches that have proven their
worth in a wide range of research areas. Here, we set out to
rectify this anachronism through the analysis of faecal material
collected throughout a dietary intervention study with inulin-
type fructans. The trial was set up as a randomised, double-
blind, placebo-controlled, cross-over trial during which healthy
adults with mild constipation consumed 12 g of chicory-derived
Orafti inulin on a daily basis along a 4-week treatment period
(ﬁgure 1). A signiﬁcant increase in stool frequency resulting
from inulin consumption was established,12 leading to a ﬁrst
positive opinion by the European Food Safety Authority on
chicory inulin and ‘maintenance of normal defecation’.13
Meanwhile, based on the scientiﬁc opinion a proprietary health
claim (article 13.5) on chicory inulin and bowel function has
been authorised by the European Commission. Using 16S
rDNA gene amplicon sequencing and matching gas chromatog-
raphy mass spectrometry (GC-MS) metabolite analysis, we ana-
lysed the samples collected to assess the impact of inulin
treatment on faecal microbiota composition and metabolite pro-
ﬁles and relate ﬁndings to the study’s clinical outcome as well as
to quality-of-life measurements.
RESULTS AND DISCUSSION
Prebiotic intervention modulates microbiome composition
First, we set out to investigate the modulating effect of inulin
consumption on colon ecosystem composition. To do so, we
deﬁned intra-individual variation of microbiota composition by
exploiting the full potential of the time-series data collected
(ﬁgure 1). Carry-over analysis of genus abundances proﬁles
ruled out potential persistence of treatment effects beyond the
duration of the washout period integrated in the study design
(Wilcoxon test, q-values >0.5; see online supplementary table
S1). Therefore, samples taken at the end of run-in periods and
placebo intervention could be regarded as snapshots of the
natural variation in the gut ecosystem. These snapshots allowed
estimating baseline individual microbiome variation over time
through calculation of reciprocal Bray-Curtis (BC) dissimilar-
ities. Comparison of baseline variation with dissimilarity
between prebiotic intervention and run-in/placebo samples
should then reveal the occurrence of a potential inulin-induced
shift in microbiome composition. Based on these assumptions,
we observed increased BC dissimilarity associated with inulin
consumption as compared with baseline variation (mean BC dis-
similarity of 0.27 vs 0.25, SD 0.09 and 0.10; Wilcoxon test,
p=0.0045). While our analyses demonstrate that the effect of
inulin supplementation on faecal microbiome composition is
sufﬁciently large to emerge against a background of baseline
temporal variation, matching analyses based on faecal volatile
metabolite proﬁles did not reveal signiﬁcant effects associated
with inulin consumption (mean BC dissimilarity of 0.29 vs
0.27, SD 0.09 and 0.09; Wilcoxon test, p=0.0731). Faecal bac-
terial metabolite concentrations off course only partially reﬂect
actual production, given the delicate balance between bacterial
production, cross-feeding and host absorption – a balance
crucial to both ecosystem stability and host health. It also needs
to be mentioned that the faecal metabolome analysis did not
cover the complete metabolome but focused on volatile metabo-
lites. As a consequence, potential changes in more polar meta-
bolites may have been missed.
Prebiotic effect size aligns with microbiome covariates
Next, we calculated the effect size of prebiotic treatment on
microbiome variation by performing a Constrained Principal
Coordinates Analysis (CAP). Using the sequencing data of all
165 samples collected, microbiome variation induced by inulin
consumption was estimated at 0.8% (permutation test, p<0.01;
ﬁgure 2). When restricting the analysis to samples taken at the
end of placebo and inulin intervention periods, estimated effect
size increased to 1.2% (permutation test, p<0.05). While these
percentages might appear rather modest (interindividual vari-
ation was estimated at 63.9% and 77.2%, respectively), they
would place the prebiotic intervention in terms of effect size
among the top covariates recently identiﬁed in a population-
level analysis of microbiome variation.14 A parallel analysis did
not reveal a signiﬁcant effect of inulin consumption on faecal
metabolite proﬁles (see online supplementary ﬁgure S1).
Capitalising on the study’s original cross-over design, we
explored the effect of inulin-type fructan fermentation on the
colon ecosystem in more detail. In terms of conventional micro-
biome markers, cross-over analysis allowed us to identify a
treatment-induced decrease in observed microbiota richness
(p<0.05; see online supplementary table S2). In spite of
reported associations with both stool consistency15 16 and
transit time,17 the observed inulin-triggered richness reduction
did not correlate with variation in Bristol Stool Scale score nor
stool frequency (Spearman’s test, r=−0.004 and −0.156,
respectively, q-values >0.05; see online supplementary table
S2). No signiﬁcant differences in microbiota evenness or diver-
sity were detected between treatment and placebo samples, nor
was sample distribution over enterotypes (prevalent microbiome
community constellations18) affected by the prebiotic interven-
tion (see online supplementary tables S2 and S3). Enterotype
shifts (an individual’s microbiome changing from one prevalent
Figure 1 Randomised, double-blind, placebo-controlled, cross-over trial. Participants were randomly distributed over two study arms, with the
order of placebo and treatment interventions switching between arms. After each run-in and intervention period, faecal samples for microbiota and
metabolite analyses as well as metadata were collected (visits V2–V5).
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microbiota constellation to another) did not occur more fre-
quently after inulin intake (19%) than after placebo intake
(19%) (see online supplementary table S3).
Selective effect on Biﬁdobacterium, Anaerostipes
and Bilophila
Genus-level cross-over analysis of amplicon proﬁles revealed
only few speciﬁc effects on microbial taxa. We observed
increased relative abundances of Biﬁdobacterium and
Anaerostipes spp. on inulin consumption (Wilcoxon test,
q-values <10−4 and <10−3, respectively; ﬁgure 3; see online
supplementary table S4). In addition, the prebiotic intervention
resulted in a decrease of the Bilophila population (q-value
<0.01; ﬁgure 3; see online supplementary table S4). While
absent for Anaerostipes and Biﬁdobacterium, we observed a
strong correlation between inulin-induced shifts in relative abun-
dances and initial numbers of Bilophila (Pearson’s correlation,
r=−0.71, p<10−6; see online supplementary ﬁgure S2 and
table S5A). No links between magnitudes of
treatment-associated shifts in relative abundance of Anaerostipes,
Biﬁdobacterium and Bilophila could be established (see online
supplementary table S5B). Using a hypothesis-driven approach,
hence reducing the burden of multiple testing correction, we
evaluated potential changes in abundances of some taxa with
previously reported susceptibility towards prebiotic stimula-
tion.19–21 No signiﬁcant shifts in Akkermansia, Eubacterium,
Faecalibacterium or Lactobacillus populations were associated
with inulin consumption (see online supplementary table S6).
Regarding faecal metabolites, cross-over analyses only revealed
increased concentrations of dodecanal after inulin consumption
(Wilcoxon test, q-value <0.001; see online supplementary table
S7). This result was conﬁrmed using Sparse Partial Least Square
Discriminant Analysis (see online supplementary ﬁgure S3).
However, it is important to note that the analytical techniques
applied do not allow detection of all metabolites present in
faecal water. Some potentially relevant metabolites (lactate, suc-
cinate and formate among others) are therefore not included in
our data. Analysis of potential correlations with inulin-
responsive genera over the complete dataset showed that the
magnitudes of dodecanal concentration shifts between consecu-
tive samples were associated with both Anaerostipes and
Biﬁdobacterium abundance variation (Spearman’s test, r=0.50,
q-value <10−9 and rho=0.29, q-value <0.05, respectively; see
online supplementary ﬁgure S4 and table S8). While dodecanal
might be of dietary origin,22 increased faecal concentrations
seem to suggest altered intestinal lipid digestion associated with
inulin treatment.23
The speciﬁc effect of treatment on ecosystem composition
(the limited number of consistently responsive taxa beyond
interindividual variation) is remarkable and contrasts with ﬁnd-
ings of amplicon sequencing studies carried out in rodents.7 8
Although a growing number of colon bacteria have been identi-
ﬁed as inulin-degraders,21 24 the speciﬁcity of the inulin inter-
vention points to Biﬁdobacterium spp., long-standing targets of
prebiotic research. Hence, our study conﬁrms the biﬁdogenic
nature of inulin-type fructans, which has been attributed to the
ability of genus to efﬁciently take up and intracellularly degrade
larger fructooligosaccharides.25 Other than biﬁdobacteria,
Anaerostipes and Bilophila ﬁgured among inulin
treatment-responsive taxa. The former is a butyrate-producing
genus comprising both inulin degraders21 and species capable of
cross-feeding on both monosaccharides and fermentation pro-
ducts resulting from primary inulin degradation by biﬁdobac-
teria.26 Of note, increased abundance of Anaerostipes was also
observed following a 3-month dietary intervention with inulin-
type fructans in obese women.27 The most prominent intestinal
isolate of the latter genus is Bilophila wadsworthia, an asacchar-
olytic, sulfate-reducing taxon, generally comprising <0.1% of
the normal human GI microbiota28 and associated with con-
sumption of an animal-based diet.29 Given its unique ability to
perform anaerobic respiration using taurine-derived sulﬁte as an
electron acceptor,30 the observed shifts in Bilophila abundances
hint to inulin-induced quantitative or qualitative changes in bile
acid production. Indeed, the – to our knowledge – only study
looking at prebiotic-induced changes in gallbladder bile proﬁles
reports an increase of up to 100% in glycine-to-taurine conjuga-
tion ratio following inulin consumption in an animal model.31
While these ﬁndings remarkably well ﬁt our observations, other
mechanistic hypotheses cannot be discarded: a lowered intes-
tinal luminal pH resulting from inulin-type fructan fermenta-
tion32 could also create a less favourable environment for
Figure 2 Prebiotic treatment accounts for 0.8% of between-sample
microbiome variation. Prebiotic treatment was used as a constraining
factor in a Principal Coordinates Analysis with Bray Curtis distance
(CAP) on samples taken at the end of intervention (o) as well as run-in
periods (x). Samples taken after inulin supplementation (blue) account
for 0.8% of between-sample microbiome variation (permutation test,
p<0.01). Genera responsive to prebiotic treatment (Biﬁdobacterium,
Anaerostipes and Bilophila, Wilcoxon test, q-value <10−4, <10−3 and
<0.01, respectively) were plotted on the ordination.
Figure 3 Inulin consumption increases Biﬁdobacterium and
Anaerostipes abundances, while Bilophila numbers drop. Genus-level
cross-over analysis of amplicon proﬁles shows increase in relative
abundances of Biﬁdobacterium and Anaerostipes spp. on prebiotic
intervention (Wilcoxon test, q-value <10−4 and <10−3, respectively)
and reveals a decrease in the Bilophila population (q-value <0.01).
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Bilophila to thrive.33 An overview of inulin-induced compos-
itional changes in the gut microbiota – complemented with
some mechanistic hypotheses – is presented in ﬁgure 4.
However, it remains important to stress that our analyses focus
on healthy, mildly constipated individuals and that care needs to
be taken when extrapolating results to phenotypically distinct
populations. For example, our results differ from those observed
in an inulin intervention in obesity-associated dysbiosis; these
differences could be due to methodological differences, and to
the different physiological context of the intervention.27 34
Likewise, in the same study, fructan consumption was found
associated with a shift in faecal short-chain fatty acid proﬁles.35
Quality of life as a potential target for prebiotic
interventions
We then evaluated associations between the genera and metabo-
lites identiﬁed as responsive to prebiotic intervention and
dietary or GI parameters. For each individual, we calculated a
distance metric assessing the shift in metadata, metabolite and
genus parameters between consecutive samples. Next, correla-
tions between the resulting parameter variations were assessed.
No signiﬁcant associations between dodecanal variation and any
of the metadata recorded were observed (see online
supplementary table S9). Similarly, no associations between vari-
ation of Biﬁdobacterium, Anaerostipes and Bilophila relative
abundances and changes in dietary patterns apart from the pre-
biotic intervention could be detected (see online supplementary
table S10). However, with regard to non-dietary metadata, a
correlation between Bilophila abundance variation and changes
in stool consistency (one-sided Spearman’s test, r=−0.22,
q-value <0.05) was found. Moreover, this analysis revealed an
association between Bilophila and Patient Assessment of
Constipation Quality of Life (PACQoL)-assessed physical dis-
comfort and treatment satisfaction scores (r=0.20, q-value
<0.05 and r=−0.30, q-value <0.01; see online supplementary
ﬁgure S5 and table S11). To our knowledge, this is a ﬁrst report
of a shift in abundance of a bacterial genus being associated
with both softer stools and a favourable change in constipation-
speciﬁc quality-of-life measures following a dietary intervention
with inulin. Based on its frequent detection in patient groups,28
its ample virulence potential36 and the potentially deleterious
nature of its metabolic end products,28 37 B. wadsworthia is
often classiﬁed as a pathobiont.37 Hence, the observed associ-
ation between Bilophila decreases on inulin consumption and
quality-of-life increase urges the need for further research on
the role of this taxon in host well-being.
CONCLUSIONS
To our knowledge, the present study is the ﬁrst to assess the
effect of inulin supplementation throughout a double-blind, ran-
domised, cross-over intervention combining ecosystem-wide
microbiome and metabolome proﬁling techniques.38 Our ana-
lyses demonstrated that the effect of inulin-type fructans supple-
mentation on the faecal microbiota is mainly restricted to
changes in Anaerostipes, Bilophila and Biﬁdobacterium relative
abundances. Despite the application of the same analyses as
used for the microbiome data on the faecal metabolites, only
dodecanal was found to increase abundance with the inulin
intervention. Hence, it can be concluded that inulin-type fruc-
tans indeed selectively inﬂuence growth of a limited number of
colon bacteria, meeting the most debated criterion of the deﬁn-
ition of prebiotics. Furthermore, we ﬁnd ﬁrst indications that
Figure 4 Overview of inulin-induced compositional changes in the gut microbiota complemented with mechanistic hypotheses. Radar plot shows
scaled variation in relative genus abundances (end riI vs end I) per individual, with decreased abundance of the genus over the inulin intervention
situated within and increased abundance outside the solid circle (zero). Variation in abundances of genera identiﬁed as inulin-responsive are
highlighted.
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reduction of Bilophila, a genus containing known pathobionts,
is associated with enhanced host well-being and could play a
role in the inulin-associated prebiotic mechanism.
METHODS
Study design
For an extensive overview of study design and procedures, we
refer to Micka et al.12 Brieﬂy, this study was set up as a rando-
mised, double-blind, placebo-controlled, cross-over trial
(Clinical Trials.gov ID: NCT02548247) targeted to investigate
the effect of chicory-derived inulin (Orafti inulin) on bowel
function in healthy individuals with constipation (see online
supplementary table S12). Ethical approval was obtained from
the Landesärztekammer Baden-Württemberg, Stuttgart,
Germany (F-2010-092#A1). Study design consisted of two
4-week intervention periods during which either 12 g of inulin
(treatment) or maltodextrin (placebo control) were consumed
on a daily basis (ﬁgure 1). Each intervention period was pre-
ceded by a 2-week run-in phase during which the subjects were
administered the placebo control. A washout phase was incorpo-
rated after the ﬁrst intervention period. Metadata collected
included personal data (age, gender, body mass index, patient’s
history of constipation and smoking status) and study-course
dependent variables such as dietary information (weight and
percentage of energy intake from fat, protein and carbohydrates
consumed), GI parameters (stool consistency, stool frequency,
feeling of bloating, incomplete emptying, straining, abdominal
discomfort and passage of gas) and PACQoL parameters (treat-
ment satisfaction and physical discomfort), which were recorded
at each visit (V2–V5).12 Faecal samples for gut microbiota
phylogenetic analyses and metabolite proﬁling were taken at
visits V2, V3, V4 and V5 (ﬁgure 1). All analyses were per-
formed on the per-protocol cohort (42 participants of the valid-
case cohort (n=44) provided stool samples).
Faecal metabolite proﬁling
Volatile organic compounds (VOC) were determined following
the method of De Preter et al.39 In brief, faecal material was sus-
pended in water and 2-ethylbutyrate was spiked in as an internal
standard. Sodium sulfate and sulfuric acid were added to the
sample to salt out and acidify the solution, respectively. VOC
were analysed using GC-MS (DSQ, Thermo Electron, San Jose,
California, USA) coupled to a purge-and-trap system (Velocity,
Teledyne Tekmar, Mason, Ohio, USA). Chromatograms were
analysed using AMDIS V.2.1 software (National Institute of
Standards and Technology (NIST), Gaithersburg, Maryland,
USA). Identiﬁcation of the metabolites detected was performed
using the NIST library. Compounds showing mass spectra with
match factors ≥90% in the NIST library were positively identi-
ﬁed. Relative indices of all VOC vs 2-ethylbutyrate as internal
standard were calculated. Metabolite proﬁles of 165 samples
were determined. A total of 382 VOC were identiﬁed and quan-
tiﬁed over all samples.
Faecal microbiota phylogenetic proﬁling
Faecal microbiota proﬁling was performed as described by
Falony et al.14 Brieﬂy, DNA was extracted from faecal material
using the MoBio PowerMicrobiome RNA isolation kit. The V4
region of the 16S rRNA gene was ampliﬁed with primer pair
515F/806R, with single multiplex identiﬁer and adaptors
according to Kozich et al.40 This primer pair has been shown to
allow adequate detection of a broad taxonomic range of colon
bacteria, including Biﬁdobacterium spp.41 Sequencing was per-
formed using Illumina MiSeq sequencer and sequencing kit
MiSeq V2 to produce 250 bp paired-end reads. After demulti-
plexing, fastq sequences were merged using FLASH42 software
with default parameters. Successfully combined reads were ﬁl-
tered based on quality (>90% of nucleotides must have quality
score 30 or higher for every read) using Fastx tool kit (http://
hannonlab.cshl.edu/fastx_toolkit/). Chimeras were removed with
UCHIME43 and each sample depth was downsized to 10,000
reads by random selection of reads. The taxonomy of reads was
assigned using RDP classiﬁer.44 In total, 165 samples of 42 indi-
viduals (3 missing samples in the per protocol cohort) were ana-
lysed covering 293 genera with an average of 80 genera per
sample.
Faecal microbiome analysis
Observed richness, estimated richness, Pielou’s evenness index
( J) and Shannon diversity index were calculated with the R
package PHYLOSEQ.45 Enterotyping (http://enterotype.embl.de/
enterotypes.html) based on Partitioning Around Medoids using
Jensen-Shannon divergence18 was performed on a combined
genus-abundance matrix including study samples complemented
with 1000 samples originating from Flemish Gut Flora Project14
in order to increase enterotyping accuracy.
Statistical analyses
All statistical analyses were performed in R (V.3.1.0). Given the
similarities between microbiome and metabolite data structure
(multidimensional, zero-enriched data matrices), analyses of
both data sets were performed following a likewise similar strat-
egy. As both genera abundances and metabolite concentrations
are not normally distributed, non-parametric tests were used.
Multiple testing correction was performed when applicable.
Carry-over analysis
A paired Wilcoxon test was used to evaluate differences between
samples taken at the start of intervention periods (V4–V2, IP
arm; ﬁgure 1) to assess possible carry-over of treatment effects.
The absence of any signiﬁcant (q-value <0.05) difference
between both samples was assumed to exclude carry-over
between interventions.
Baseline versus treatment analysis
Mean BC dissimilarity between non-treatment samples (end riI,
riP and P; ﬁgure 1) was compared with mean dissimilarity
between treatment (end I) and non-treatment samples using a
one-sided Wilcoxon test, both on microbiome and metabolome
data, in order to assess ecosystem-level effects of the inulin
intervention. In parallel, BC dissimilarity induced by placebo
(end riP vs end P) and inulin (end riI vs end I) intervention was
compared using a paired Wilcoxon test on both dissimilarities.
Constrained analysis of principal coordinates
To determine the effect of inulin intake on the microbial com-
position, we applied CAP (R package VEGAN,46 function cap
scale) using BC dissimilarity as a distance metric and with inulin
as the constraining factor and participant’s ID as a conditioning
factor. Signiﬁcance was calculated with a permutation test (func-
tion anova.cca, default parameters). Genera responsive to inulin
treatment were ﬁtted onto the ordination (function envﬁt).
Cross-over analysis
Matching the speciﬁc format of the cross-over design, we used
dedicated statistical analyses to assess the potential effect of
inulin treatment.47 In short, for each individual and parameter
under study (richness, evenness, taxon or metabolite
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abundance), read-outs observed at the end of each intervention
period were subtracted (V5–V3; ﬁgure 1). Cross-over analysis
consisted in evaluating differences between study arms (IP vs PI;
ﬁgure 1) in the resulting output using Wilcoxon test, imposing
cohort stratiﬁcation when required (enterotype, gender) and
applying Benjamini Hochberg false discovery rate (BH-FDR;48)
to correct for multiple testing.
Correlations
Correlations between variation in observed richness and both
stool consistency and frequency induced by inulin treatment
(end riI vs end I) were assessed using Spearman’s correlation.
For genera identiﬁed as responsive to inulin treatment, corre-
lations between the magnitude of the observed shifts in relative
abundances on inulin consumption (end riI vs end I) and
their initial abundances (end riI) were assessed using Pearson’s
correlation. Also correlations between the magnitudes of
inulin-induced shifts (end riI vs end I) of different responsive
genera were evaluated using Pearson’s correlation. Correlations
between shifts in relative abundance of responsive genera and
responsive metabolites (consecutive samples: V3–V2, V4–V3,
V5–V4, using all 165 samples) were tested using Spearman’s
correlation.
Sparse partial least square discriminant analysis
Sparse partial least square discriminant analysis (sPLS-DA) was
performed with the R package mixOmics on all 165 samples of
the per-protocol cohort. Inulin supplementation class (yes (41)
vs no (124)) was used as a stratifying factor on the faecal metab-
olite matrix. Removing all metabolites with near to zero vari-
ance (function nearZeroVar), the faecal metabolite matrix was
reduced to 147 variables. The optimal number of components
was chosen based on the averaged balanced classiﬁcation error
rate with centroids distance over 50 repeats of a 10-fold cross-
validation of a PLS-DA model with 10 components (function
perf ). The optimal number of selected variables for each compo-
nent was chosen based on the lowest average balanced classiﬁca-
tion error rate with centroids after tuning of the sPLS-DA
model (function tune.spldsda; using 4 components and 10-fold
cross-validation with 50 repeats; see online supplementary
ﬁgure S3). Stability frequency scores of the selected metabolites
were calculated (function perf ) on the ﬁnal sPLS-DA model
with 10-fold cross-validation and 10 repetitions.
Integrated microbiota, metabolite and metadata analysis
Using all four samples collected during the study, shifts in abun-
dance of inulin-responsive genera, concentrations of
treatment-affected metabolites and metadata read-outs between
consecutive samples were calculated, adjusting for missing
samples. Correlations between shifts were evaluated using a
Spearman’s test. BH-FDR was applied on all tests to correct for
multiple testing.
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